Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH)

Aurinia Pharmaceuticals Inc. ( AUPH ) has had an exciting few months, with an earnings update showing continued Lupkynis growth, a competitor's drug being approved for lupus nephritis, and a request for information from the FDA. I rated AUPH aScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclo ...